Endocannabinoids in cognition and dependence

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 66, Issue 2-3, 2002, Pages 269-285

  Lichtman, A H ^a   Varvel, S A ^a   Martin, B R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DEXANABINOL; DRONABINOL; GLUTAMIC ACID; METHANANDAMIDE; RIMONABANT; CANNABINOID RECEPTOR; DRUG RECEPTOR; ENDOCANNABINOID; ICOSANOID;

AMNESIA; CHOLINERGIC TRANSMISSION; COGNITION; COGNITIVE DEFECT; DRUG DEPENDENCE; DRUG INTOXICATION; GABAERGIC TRANSMISSION; HIPPOCAMPUS; KNOCKOUT MOUSE; MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; TRANSGENIC MOUSE; WITHDRAWAL SYNDROME; ADDICTION; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; HUMAN; LEARNING; METABOLISM; NERVE CELL PLASTICITY; OPIATE ADDICTION; PHYSIOLOGY;

CANNABIS; MUS MUSCULUS;

ANIMALS; CANNABINOIDS; COGNITION; EICOSANOIDS; ENDOCANNABINOIDS; HUMANS; LEARNING; MEMORY; NEURONAL PLASTICITY; OPIOID-RELATED DISORDERS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SUBSTANCE-RELATED DISORDERS;

EID: 0036019413     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2001.0351     Document Type: Article

References (152)

1. Control of pain initiation by endogenous cannabinoids
2. Pain modulation by release of the endogenous cannabinoid anandamide
3. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia
4. Leptin-regulated endocannabinoids are involved in maintaining food intake
5. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR141716
6. SR141716A enhances spatial memory as assessed in a radial-arm maze task in rats
7. Mesolimbic dopaminergic decline after cannabinoid withdrawal
8. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
9. Cannabis: Effects on memory and the cholinergic limbic system
10. Effects of smoked marijuana on human performance: A critical review
11. 9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task specific firing of hippocampal cells
12. Cannabinoids, hippocampal function and memory
13. Complete adaptation to the memory disruptive effects of delta-9-thc following 35 days of exposure
14. Delta-9-tetrahydrocannabinol impairs visual recognition memory but not discrimination learning in rhesus monkeys
15. Δ9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance
16. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta-9-tetrahydrocannabinol or anandamide
17. SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats
18. Acute effects of marijuana smoke on complex operant behavior in rhesus monkeys
19. Acute effects of delta-9-tetrahydrocannabinol in rhesus monkeys as measured by performance in a battery of complex operant tests
20. Cannabinoid ligands and their effects on learning and performance in rhesus monkeys
21. Effects of the cannabinoid ligand SR141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys
22. The radial arm maze as a tool in behavioral pharmacology
23. 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: Blockade of dopaminergic effects with HA966
24. Effects of chronic delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze
25. 9-tetrahydrocannabinol (THC) on memory in the rat
26. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats
27. Effect of delta 9-tetrahydrocannabinol on short-term memory in the rat
28. 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism
29. Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats
30. Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task
31. Differential effects of delta9-THC on spatial reference and working memory in mice
32. The effects of anandamide on memory consolidation in mice involve both D1 and D2 dopamine receptors
33. Anandamide modulates sleep and memory in rats
34. Strain-dependent involvement of D1 and D2 dopamine receptors in muscarinic cholinergic influences on memory storage
35. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats
36. Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats
37. 9-tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain
38. Differences in G-protein activation by μ- and δ-opioid, and cannabinoid, receptors in rat striatum
39. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity
40. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor
41. Cannabinoid-precipitated withdrawal: A time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression
42. Inhibitory effects of SR141716A on G-protein activation in rat brain
43. Enhancement of memory in cannabinoid CB1 receptor knock-out mice
44. Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors
45. Characterization and localization of cannabionoid receptors in rat brain: A quantitative in vitro autoradiographic study
46. 3H]-SR141716A a selective brain (CB1) cannabinoid receptor antagonist in rodent brain
47. Localization of cannabinoid receptor mRNA in rat brain
48. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons
49. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB(1)
50. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat
51. Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function
52. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: Evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain
53. 9-tetrahydrocannabinol in the rat hippocampus, in vitro
54. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice
55. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice
56. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: Reversal by SR141716A, a selective antagonist of CB1 cannabinoid receptors
57. A second endogenous cannabinoid that modulates long-term potentiation
58. Mechanism of cannabinoid effects on long-term potential and depression in hippocampal CA1 neurons
59. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture
60. 9-tetrahydrocannabinol and cannabidiol on sodium-dependent high affinity choline uptake in the rat hippocampus
61. 9-tetrahydrocannabinol within the septal-hippocampal cholinergic pathway of rat brain
62. Electrically evoked acetylcholine release from hippocampal slices in inhibited by the cannabinoid receptor agonist, WIN55212-2, and is potentiated by the cannabinoid antagonist, SR141716A
63. Examination of the effect of the cannabinoid receptor agonist, CP55,940, on electrically evoked transmitter release from rat brain slices
64. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice
65. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes
66. Inhibition of hippocampal acetylcholine release after acute and repeated delta9-tetrahydrocannabinol in rats
67. Inhibition of hippocampal acetylcholine release by cannabinoids: Reversal by SR141716A
68. Cannabinoids decrease acetylcholine release in the medial-prefontal cortex and hippocampus, reversal by SR141716 A
69. Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice
70. Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons
71. Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture
72. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures
73. Selective memory impairment by phencyclidine in rats
74. A novel NMDA antagonist, MK-801, impairs performance in a hippocampal-dependent spatial learning task
75. Are glutamate receptors specifically implicated in some forms of memory processes?
76. Phencyclidine disrupts long- but not short-term memory within a spatial learning task
77. Phencyclidine injections into the dorsal hippocampus disrupt long- but not short-term memory within a spatial learning task
78. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons
79. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain
80. Cannabinoid CB1 receptors are localized primarily on cholecystokinin- containing GABAergic interneurons in the rat hippocampal formation
81. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus
82. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus
83. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
84. Cannabinoids: Influence on neurotransmitter uptake in rat brain synaptosomes
85. Effect of cannabinoids on neurotransmitter uptake, atpase activity and morphology of mouse brain synaptosomes
86. The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake
87. 9-tetrahydrocannabinol
88. Cannabinoid receptor activation in CA1 pyramidal cells in adult rat hippocampus
89. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals
90. One year follow-up of cannabis dependence among long-term users in Sydney, Australia
91. Relationships between frequency and quantity of marijuana use and last year proxy dependence among adolescents and adults in the United States
92. Task force on DSM-IV
93. Abstinence symptoms following oral THC administration to humans
94. Abstinence symptoms following smoked marijuana in humans
95. Clinical studies of cannabis tolerance and dependence
96. The 30-day trip - Clinical studies of cannabis tolerance and dependence
97. Physiological and psychological dependence on THC in rhesus monkeys
98. Characteristics of tetrahydrocannabinol tolerance
99. Failure to obtain 'cannabis-directed behavior' and abstinence syndrome in rats chronically treated with cannabis sativa extracts
100. 9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal
101. Dependence on tetrahydrocannabinol in rhesus monkeys
102. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
103. 9-tetrahydrocannabinol-induced responses and apparent agonist activity
104. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide
105. Discriminative stimulus effects of CP 55,940 and structurally dissamilar cannabinoids in rats
106. 9-tetrahydrocannabinol precipated by a cannabinoid receptor antagonist
107. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR141716A
108. Activitation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal
109. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol
110. Acute and chronic cannabinoid effects: Characterization of precipitated withdrawal in dogs
111. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice
112. CB1 receptor antagonist precipitates withdrawal in mice exposed to delta9-tetrahydrocannabinol
113. Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum
114. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice
115. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential
116. The biodisposition and metabolism of anandamide in mice
117. Precipitated and spontaneous withdrawal in rats tolerant to anandamide
118. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
119. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
120. Precipitated cannabinoid withdrawal is reversed by delta(9)-tetrahydrocannabinol or clonidine
121. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR141716A in naive mice
122. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
123. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: Evaluation of the interest in pharmacotherapy of opioid addiction
124. The cloning of a family of genes that encode the melanocortin receptors
125. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in the whole brain
126. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol
127. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP55,940 on adenylyl cyclase in the cerebellum of CP55,940-tolerant mice
128. Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system
129. 35]GTPγS autoradiography in rat brain
130. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: Behavioral and cellular responses after acute and chronic treatments
131. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors
132. Dopaminergic system does not play a major role in the precipitated cannabinoid withdrawal syndrome
133. A comparison of clonidine with morphine for antinociceptive and antiwithdrawal actions
134. Clonidine blocks acute opiate-withdrawal symptoms
135. Clonidine and the treatment of the opiate withdrawal syndrome
136. 1 cannabiniod receptor antagonist-induced opiate withdrawal in morphine-dependent rats
137. Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice
138. Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome
139. 9-tetrahydrocannabinol
140. Morphine-dependent rats: Blockade of precipitated abstinence by tetrahydrocannabinol
141. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine
142. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone- precipitated withdrawal signs in morphine-dependent mice
143. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome
144. 9-tetrahydrocannabinol-tolerant rats
145. 9-tetrahydrocannabinol: Tolerance to the stimulus effects
146. The endogenous cannabinoid receptor agonist anandamide impairs memory in rats
147. D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration
148. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after delta(9)-tetrahydrocannabinol withdrawal
149. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2
150. SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists